Persistent post-treatment ctDNA detection was associated with disease progression, supporting the potential role of HPV16 ctDNA in risk-adapted surveillance following curative-intent treatment and providing clinically meaningful prognostic information in HPV-associated OPC.
L. Torrens, P. Chopard, V. Gaborieau et al.· European Journal of Cancer· 0 citations
To address the absence of a unified weighting scheme for clinical and pathological predictors of malignant transformation in OPMDs, a targeted expert survey was conducted within the COST action INTERCEPTOR Working Group 2 (clinician-researchers with formal expertise in OPMDs).
H. Çobanoğlu, S. A. Khurram, A. Chaurasia et al.· Critical reviews in oncology...· 0 citations
A narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured.
Farhood Farahnak, W. El-Deiry, Yves A. Lussier et al.· JCO Global Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.